Enlivex Therapeutics Ltd. (ENLV.TA)
ILA 433.2
(5.2%)
ILA 433.2
(5.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -29.06 Million USD | 6.41% |
| 2022 | -31.06 Million USD | -114.68% |
| 2021 | -14.46 Million USD | -22.36% |
| 2020 | -11.82 Million USD | -26.0% |
| 2019 | -9.38 Million USD | -121.22% |
| 2018 | -4.24 Million USD | 28.65% |
| 2017 | -5.94 Million USD | 62.89% |
| 2016 | -16.02 Million USD | -4.28% |
| 2015 | -15.36 Million USD | -118.81% |
| 2014 | -7.02 Million USD | -513.28% |
| 2013 | -1.14 Million USD | -400.0% |
| 2012 | -229 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.14 Million USD | 54.48% |
| 2024 Q2 | -3.09 Million USD | 25.22% |
| 2023 Q2 | -6.79 Million USD | 5.9% |
| 2023 Q1 | -7.21 Million USD | -0.4% |
| 2023 Q3 | -5.96 Million USD | 12.21% |
| 2023 Q4 | -9.09 Million USD | -52.52% |
| 2023 FY | -29.06 Million USD | 6.41% |
| 2022 Q2 | -9.91 Million USD | -20.52% |
| 2022 Q3 | -5.73 Million USD | 42.17% |
| 2022 Q4 | -7.18 Million USD | -25.4% |
| 2022 FY | -31.06 Million USD | -114.68% |
| 2022 Q1 | -8.22 Million USD | -73.67% |
| 2021 Q4 | -4.73 Million USD | -38.32% |
| 2021 FY | -14.46 Million USD | -22.36% |
| 2021 Q3 | -3.42 Million USD | -10.17% |
| 2021 Q2 | -3.1 Million USD | 2.88% |
| 2021 Q1 | -3.2 Million USD | 45.43% |
| 2020 Q1 | -794 Thousand USD | 72.31% |
| 2020 Q4 | -5.86 Million USD | -175.95% |
| 2020 Q3 | -2.12 Million USD | 30.12% |
| 2020 FY | -11.82 Million USD | -26.0% |
| 2020 Q2 | -3.04 Million USD | -283.0% |
| 2019 Q2 | -1.46 Million USD | 45.18% |
| 2019 FY | -9.38 Million USD | -121.22% |
| 2019 Q4 | -2.86 Million USD | -19.91% |
| 2019 Q3 | -2.39 Million USD | -63.66% |
| 2019 Q1 | -2.66 Million USD | -68.14% |
| 2018 Q4 | -1.58 Million USD | -43.83% |
| 2018 FY | -4.24 Million USD | 28.65% |
| 2018 Q1 | -1.02 Million USD | -80.14% |
| 2018 Q2 | -531 Thousand USD | 48.2% |
| 2018 Q3 | -1.1 Million USD | -107.53% |
| 2017 Q2 | -1.63 Million USD | 38.88% |
| 2017 Q1 | -2.67 Million USD | 13.05% |
| 2017 FY | -5.94 Million USD | 62.89% |
| 2017 Q4 | -569 Thousand USD | 46.87% |
| 2017 Q3 | -1.07 Million USD | 34.42% |
| 2016 Q1 | -4.59 Million USD | 4.87% |
| 2016 Q4 | -3.07 Million USD | 34.2% |
| 2016 Q3 | -4.67 Million USD | -26.73% |
| 2016 Q2 | -3.68 Million USD | 19.79% |
| 2016 FY | -16.02 Million USD | -4.28% |
| 2015 Q3 | -3.55 Million USD | 3.66% |
| 2015 Q2 | -3.68 Million USD | -11.73% |
| 2015 Q4 | -4.82 Million USD | -35.99% |
| 2015 Q1 | -3.29 Million USD | -4.66% |
| 2015 FY | -15.36 Million USD | -118.81% |
| 2014 Q3 | -2.11 Million USD | -89.5% |
| 2014 Q4 | -3.15 Million USD | -49.31% |
| 2014 Q1 | -645 Thousand USD | 16.99% |
| 2014 Q2 | -1.11 Million USD | -72.71% |
| 2014 FY | -7.02 Million USD | -513.28% |
| 2013 Q3 | -195 Thousand USD | -44.44% |
| 2013 FY | -1.14 Million USD | -400.0% |
| 2013 Q2 | -135 Thousand USD | 0.0% |
| 2013 Q4 | -777 Thousand USD | -298.46% |
| 2012 FY | -229 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Matricelf Ltd | -12.48 Million ILA | -132.805% |